THO Seed Fund
11026 Olive Blvd., Creve Coeur, MO, United States
Overview
THO Seed Fund generally refers to an early-stage investment fund that provides capital to startups and entrepreneurs to help them develop their ideas from inception to scalable businesses.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 0
Sector focus
- Biotechnology
Investment portfolio
- Faeth Therapeutics
Participated · Equity · Oct 2025
Faeth Therapeutics, headquartered in Austin, Texas, is advancing multi-node therapies that block cancer growth signals while controlling tumor fuel supply. Its proprietary, AI-driven MetabOS platform uncovers metabolic dependencies in tumors and other diseases, guiding the development of therapeutic and nutritional interventions. The company’s lead program is a Phase 2 study in endometrial cancer that is expected to deliver a full data readout in Q3 2026. Additional plans include a Phase 1 trial in locally advanced rectal cancer using a non-essential amino acid-restricted regimen and an investigational program for Hereditary Tyrosinemia Type 1, the first application of MetabOS beyond oncology. Founded in 2019 by noted scientists Lewis Cantley, Siddhartha Mukherjee, Karen Vousden, Scott Lowe, and Greg Hannon, the company is led by CEO Anand Parikh. To date, Faeth has raised $92 million in capital to fund its pipeline and expand the MetabOS platform.
Team
No current team members are available.